Cabaletta Bio Q3 2024: cash $183M, 40 U.S. sites recruiting; EMA greenlights lupus trial

Cabaletta Bio, Inc.

2024-Q3 EPS reported -$1.69

R&D expenses $26.3M (up 91% YoY); G&A $6.8M (up 39%); cash $183.0M expected to fund ops into H1 2026.
16 patients enrolled, 10 dosed across RESET program as of Nov 12; 40 U.S. clinical sites actively recruiting.
EMA allowed CTA for RESET-SLE trial in Europe; myositis, lupus, scleroderma data presented at ACR weekend.
Gerwin Winter appointed SVP Head of International; Nicolette Sherman named CHRO replacing retiring Martha O'Connor.
Investor call Nov 18 to review ACR data; Jefferies London conference Nov 20.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.